Molecular structure of Lazabemide hydrochloride, CAS Number: 103878-83-7
Lazabemide hydrochloride (CAS 103878-83-7)
Alternate Names:
Ro 19-6327
Application:
Lazabemide hydrochloride is a selective and reversible monoamine oxidase B inhibitor
CAS Number:
103878-83-7
Molecular Weight:
236.1
Molecular Formula:
C8H10ClN3O•HCl
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Lazabemide hydrochloride is a salt form of Lazabemide, a reversible and selective inhibitor of MAO-B (monoamine oxidase-B). This compound has been found to contain antioxidant activity. Mechanistic studies show that Lazabemide inhibits oxidative damage by interacting with the membrane lipid bilayer of cells and preventing propagation of free radicals. The inhibition of membrane lipid peroxidation by Lazabemide has been reported to be independent of MAO-B interactions.
Lazabemide hydrochloride (CAS 103878-83-7) References
- Antioxidant activity of the monoamine oxidase B inhibitor lazabemide. | Mason, RP., et al. 2000. Biochem Pharmacol. 60: 709-16. PMID: 10927030
- Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. | Saura, J., et al. 1992. J Neurosci. 12: 1977-99. PMID: 1578281
- The effects of lifelong treatment with MAO inhibitors on amino acid levels in rat brain. | Strolin Benedetti, M., et al. 1990. J Neural Transm Park Dis Dement Sect. 2: 239-48. PMID: 2078306
- Role of monoamine oxidase A and B in the deamination of newly-formed dopamine in the rat kidney. | Fernandes, MH. and Soares-da-Silva, P. 1990. J Neural Transm Suppl. 32: 155-9. PMID: 2089083
- MAO-B inhibition in rabbit tissues and in human platelets by Ro 19-6327 shows similar time-course. | Kettler, R., et al. 1990. J Neural Transm Suppl. 32: 211-4. PMID: 2089093
- Effects of MAO-A and MAO-B selective inhibitors Ro 41-1049 and Ro 19-6327 on the deamination of newly formed dopamine in the rat kidney. | Fernandes, MH. and Soares-da-Silva, P. 1990. J Pharmacol Exp Ther. 255: 1309-13. PMID: 2124622
- From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. | Da Prada, M., et al. 1990. J Neural Transm Suppl. 29: 279-92. PMID: 2193111
- [3H]Ro 19-6327: a reversible ligand and affinity labelling probe for monoamine oxidase-B. | Cesura, AM., et al. 1989. Eur J Pharmacol. 162: 457-65. PMID: 2744079
- Interactions of the novel inhibitors of MAO-B Ro 19-6327 and Ro 16-6491 with the active site of the enzyme. | Cesura, AM., et al. 1988. Pharmacol Res Commun. 20 Suppl 4: 51-61. PMID: 3244727
- In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl. | Bondiolotti, GP., et al. 1995. Biochem Pharmacol. 50: 97-102. PMID: 7605351
- The effects of administration of monoamine oxidase-B inhibitors on rat striatal neurone responses to dopamine. | Berry, MD., et al. 1994. Br J Pharmacol. 113: 1159-66. PMID: 7889269
- Effect of type A and B monoamine oxidase selective inhibition by Ro 41-1049 and Ro 19-6327 on dopamine outflow in rat kidney slices. | Pestana, M. and Soares-da-Silva, P. 1994. Br J Pharmacol. 113: 1269-74. PMID: 7889283
- [3H]Rilmenidine-labelled imidazoline-receptor binding sites co-localize with [3H]2-(benzofuranyl)-2-imidazoline-labelled imidazoline-receptor binding sites and monoamine oxidase-B in rabbit, but not rat, kidney. | King, PR., et al. 1998. J Auton Nerv Syst. 72: 118-28. PMID: 9851560
Inhibitor of:
Enzyme, and MAO-B.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Lazabemide hydrochloride, 10 mg | sc-202208 | 10 mg | $79.00 | |||
Lazabemide hydrochloride, 50 mg | sc-202208A | 50 mg | $446.00 |